Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) have earned a consensus rating of “Buy” from the ten brokerages that are covering the company, MarketBeat Ratings reports. Ten investment analysts have rated the stock with a buy recommendation. The average 12 month price target among brokers that have updated their coverage on the […]